50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,705.33 (+1.59%)
DOW   29,616.65 (+1.65%)
QQQ   277.81 (+1.21%)
AAPL   147.18 (-3.02%)
MSFT   239.93 (+1.49%)
META   139.84 (+4.05%)
GOOGL   99.45 (+2.00%)
AMZN   116.94 (+2.21%)
TSLA   282.24 (-0.25%)
NVDA   126.46 (+1.88%)
NIO   17.12 (-0.41%)
BABA   80.34 (+3.17%)
AMD   68.19 (+1.52%)
T   15.87 (+0.89%)
MU   50.59 (+0.02%)
CGC   2.97 (+3.85%)
F   12.04 (+1.09%)
GE   64.55 (+0.12%)
DIS   98.66 (+2.93%)
AMC   7.54 (+1.21%)
PYPL   88.68 (+3.42%)
PFE   44.45 (+0.82%)
NFLX   240.27 (+7.09%)
S&P 500   3,705.33 (+1.59%)
DOW   29,616.65 (+1.65%)
QQQ   277.81 (+1.21%)
AAPL   147.18 (-3.02%)
MSFT   239.93 (+1.49%)
META   139.84 (+4.05%)
GOOGL   99.45 (+2.00%)
AMZN   116.94 (+2.21%)
TSLA   282.24 (-0.25%)
NVDA   126.46 (+1.88%)
NIO   17.12 (-0.41%)
BABA   80.34 (+3.17%)
AMD   68.19 (+1.52%)
T   15.87 (+0.89%)
MU   50.59 (+0.02%)
CGC   2.97 (+3.85%)
F   12.04 (+1.09%)
GE   64.55 (+0.12%)
DIS   98.66 (+2.93%)
AMC   7.54 (+1.21%)
PYPL   88.68 (+3.42%)
PFE   44.45 (+0.82%)
NFLX   240.27 (+7.09%)
S&P 500   3,705.33 (+1.59%)
DOW   29,616.65 (+1.65%)
QQQ   277.81 (+1.21%)
AAPL   147.18 (-3.02%)
MSFT   239.93 (+1.49%)
META   139.84 (+4.05%)
GOOGL   99.45 (+2.00%)
AMZN   116.94 (+2.21%)
TSLA   282.24 (-0.25%)
NVDA   126.46 (+1.88%)
NIO   17.12 (-0.41%)
BABA   80.34 (+3.17%)
AMD   68.19 (+1.52%)
T   15.87 (+0.89%)
MU   50.59 (+0.02%)
CGC   2.97 (+3.85%)
F   12.04 (+1.09%)
GE   64.55 (+0.12%)
DIS   98.66 (+2.93%)
AMC   7.54 (+1.21%)
PYPL   88.68 (+3.42%)
PFE   44.45 (+0.82%)
NFLX   240.27 (+7.09%)
S&P 500   3,705.33 (+1.59%)
DOW   29,616.65 (+1.65%)
QQQ   277.81 (+1.21%)
AAPL   147.18 (-3.02%)
MSFT   239.93 (+1.49%)
META   139.84 (+4.05%)
GOOGL   99.45 (+2.00%)
AMZN   116.94 (+2.21%)
TSLA   282.24 (-0.25%)
NVDA   126.46 (+1.88%)
NIO   17.12 (-0.41%)
BABA   80.34 (+3.17%)
AMD   68.19 (+1.52%)
T   15.87 (+0.89%)
MU   50.59 (+0.02%)
CGC   2.97 (+3.85%)
F   12.04 (+1.09%)
GE   64.55 (+0.12%)
DIS   98.66 (+2.93%)
AMC   7.54 (+1.21%)
PYPL   88.68 (+3.42%)
PFE   44.45 (+0.82%)
NFLX   240.27 (+7.09%)
NYSE:GKOS

Glaukos - GKOS Stock Forecast, Price & News

$52.15
+1.04 (+2.03%)
(As of 09/28/2022 12:29 PM ET)
Add
Compare
Today's Range
$51.46
$52.39
50-Day Range
$48.00
$58.49
52-Week Range
$33.33
$64.49
Volume
3,319 shs
Average Volume
762,870 shs
Market Capitalization
$2.47 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$57.38

Glaukos MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
10.4% Upside
$57.38 Price Target
Short Interest
Bearish
8.35% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.95
Upright™ Environmental Score
News Sentiment
-0.05mentions of Glaukos in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$178,220 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.26) to ($1.69) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.70 out of 5 stars

Medical Sector

878th out of 1,071 stocks

Surgical & Medical Instruments Industry

93rd out of 106 stocks

GKOS stock logo

About Glaukos (NYSE:GKOS) Stock

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.

Receive GKOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter.

GKOS Stock News Headlines

Glaukos Co. (NYSE:GKOS) Given Average Rating of "Hold" by Brokerages
See More Headlines
Receive GKOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter.

GKOS Company Calendar

Last Earnings
8/03/2022
Today
9/28/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Employees
727
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$57.38
High Stock Price Forecast
$68.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+10.0%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
9 Analysts

Profitability

Net Income
$-49,590,000.00
Pretax Margin
-19.33%

Debt

Sales & Book Value

Annual Sales
$294.01 million
Book Value
$12.52 per share

Miscellaneous

Free Float
43,500,000
Market Cap
$2.47 billion
Optionable
Optionable
Beta
1.42

Key Executives

  • Mr. Thomas William Burns (Age 61)
    Chairman & CEO
    Comp: $1.96M
  • Mr. Joseph E. GilliamMr. Joseph E. Gilliam (Age 45)
    Pres & COO
    Comp: $991.52k
  • Mr. Chris M. Calcaterra (Age 62)
    Exec. VP of Global Commercial Operations
    Comp: $1M
  • Dr. Mory Gharib Ph.D.
    Co-Founder
  • Mr. Alex R. Thurman (Age 52)
    Sr. VP & CFO
  • Mr. Christopher William Lewis
    VP of Investor Relations & Corp. Affairs
  • Ms. Diane W. Biagianti (Age 62)
    Sr. VP & Gen. Counsel
  • Ms. Diana A. Scherer
    VP of Compliance & Deputy Gen. Counsel
  • Ms. Michele M. Allegretto
    Sr. VP of HR
  • Mr. David S. Haffner
    Sr. VP of New Technologies













GKOS Stock - Frequently Asked Questions

Should I buy or sell Glaukos stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 1 sell rating, 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GKOS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GKOS, but not buy additional shares or sell existing shares.
View GKOS analyst ratings
or view top-rated stocks.

What is Glaukos' stock price forecast for 2022?

9 Wall Street analysts have issued 1-year price objectives for Glaukos' stock. Their GKOS share price forecasts range from $40.00 to $68.00. On average, they expect the company's share price to reach $57.38 in the next year. This suggests a possible upside of 12.3% from the stock's current price.
View analysts price targets for GKOS
or view top-rated stocks among Wall Street analysts.

How have GKOS shares performed in 2022?

Glaukos' stock was trading at $44.44 at the beginning of the year. Since then, GKOS shares have increased by 15.0% and is now trading at $51.11.
View the best growth stocks for 2022 here
.

Are investors shorting Glaukos?

Glaukos saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 2,550,000 shares, an increase of 58.4% from the August 15th total of 1,610,000 shares. Based on an average trading volume of 543,000 shares, the days-to-cover ratio is presently 4.7 days. Approximately 5.6% of the company's shares are short sold.
View Glaukos' Short Interest
.

When is Glaukos' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our GKOS earnings forecast
.

How were Glaukos' earnings last quarter?

Glaukos Co. (NYSE:GKOS) released its earnings results on Wednesday, August, 3rd. The medical instruments supplier reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.44) by $0.39. The medical instruments supplier had revenue of $72.69 million for the quarter, compared to analysts' expectations of $67.61 million. Glaukos had a negative net margin of 19.35% and a negative trailing twelve-month return on equity of 13.82%.

What guidance has Glaukos issued on next quarter's earnings?

Glaukos updated its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $275.00 million-$280.00 million, compared to the consensus revenue estimate of $274.39 million.

What is Thomas W. Burns' approval rating as Glaukos' CEO?

10 employees have rated Glaukos Chief Executive Officer Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among the company's employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Glaukos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and Boeing (BA).

When did Glaukos IPO?

(GKOS) raised $76 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

What is Glaukos' stock symbol?

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

Who are Glaukos' major shareholders?

Glaukos' stock is owned by a number of institutional and retail investors. Top institutional investors include Artisan Partners Limited Partnership (4.15%), State Street Corp (3.59%), Point72 Asset Management L.P. (2.79%), Assenagon Asset Management S.A. (1.90%), Riverbridge Partners LLC (1.36%) and Riverbridge Partners LLC (1.30%). Insiders that own company stock include Gilbert H Kliman, Joseph E Gilliam, Thomas William Burns and William J Phd Link.
View institutional ownership trends
.

How do I buy shares of Glaukos?

Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Glaukos' stock price today?

One share of GKOS stock can currently be purchased for approximately $51.11.

How much money does Glaukos make?

Glaukos (NYSE:GKOS) has a market capitalization of $2.42 billion and generates $294.01 million in revenue each year. The medical instruments supplier earns $-49,590,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis.

How many employees does Glaukos have?

The company employs 727 workers across the globe.

How can I contact Glaukos?

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The official website for the company is www.glaukos.com. The medical instruments supplier can be reached via phone at (949) 367-9600, via email at investors@glaukos.com, or via fax at 949-367-9984.

This page (NYSE:GKOS) was last updated on 9/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.